Novel combination of celecoxib and proteasome inhibitor MG132 provides synergistic antiproliferative and proapoptotic effects in human liver tumor cells.
Cusimano
Antonella
A
Institute of Biomedicine and Molecular Immunology Alberto Monroy, Palermo, Italy.
Azzolina
Antonina
A
Iovanna
Juan L
JL
Bachvarov
Dimcho
D
McCubrey
James A
JA
D'Alessandro
Natale
N
Montalto
Giuseppe
G
Cervello
Melchiorre
M
D017209:Apoptosis / Q000187:drug effects; D015153:Blotting, Western; D000068579:Celecoxib; D049109:Cell Proliferation / Q000187:drug effects; D052246:Cyclooxygenase 2 Inhibitors / Q000494:pharmacology*; D015853:Cysteine Proteinase Inhibitors / Q000494:pharmacology*; D004357:Drug Synergism; D005434:Flow Cytometry; D056945:Hep G2 Cells; D006801:Humans; D007976:Leupeptins / Q000494:pharmacology*; D011720:Pyrazoles / Q000494:pharmacology*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013449:Sulfonamides / Q000494:pharmacology*
D052246:Cyclooxygenase 2 Inhibitors; D015853:Cysteine Proteinase Inhibitors; D007976:Leupeptins; D011720:Pyrazoles; D013449:Sulfonamides; D000068579:Celecoxib; C072553:benzyloxycarbonylleucyl-leucyl-leucine aldehyde